Olin has become a striking value-investing case. Shares recently traded around $16.50, close to their 52-week low of $16.35 and down roughly 46% from the 52-week high of $30.46. The decline reflects a serious earnings downturn, but the valuation is becoming increasingly difficult to ignore. Second-quarter 2026 revenue was $1.74 billion, down slightly year over year and below expectations. The company reported a $13.3 million net loss, or $0.12 per share, although adjusted EBITDA improved to $191.3 million from $176.1 million. The problem is that profitability remains weak. Olin has reported losses in recent quarters, while the chemical business faces difficult market conditions and cyclical pricing pressure. Trailing net income remains negative. There is nevertheless a potential recovery story. Adjusted EBITDA is improving sequentially, while management continues focusing on cost control and cash generation. The dividend remains $0.20 per quarter, or $0.80 annually, giving the shares a yield of almost 5% at the current price. The value case depends on chemical margins recovering and earnings returning to profitability. The risks are prolonged industry weakness, debt, volatile raw-material costs and continued losses. The next major catalyst is the third-quarter report, expected in late October. This review is for informational and educational purposes only, not financial advice.

Oxford Industries has suffered a brutal reset. Shares closed around $28.05, down more than 34% over the past year and nearly 27% since the end of August. The collapse accelerated after management sharply reduced its fiscal 2026 outlook. Is the market now pricing in too much bad news? Second-quarter revenue fell 2.2% to $394 million, although adjusted earnings per share increased to $1.34 from $1.26. The bigger problem is the outlook: management now expects fiscal 2026 revenue of $1.43–$1.47 billion and adjusted earnings per share of only $1.60–$2.00, versus $2.11 previously. Lilly Pulitzer remains under pressure, while tariffs and weaker consumer demand are weighing on profitability. There are positives. Gross margins have been improving, cash flow has helped reduce debt, and Tommy Bahama continues to perform relatively well. The company also pays a $0.70 quarterly dividend, recently increased from $0.69. The value case is straightforward: a depressed share price, recognizable brands, improving margins and potential earnings recovery. The risks are weak sales, continued pressure at Lilly Pulitzer, tariffs and a dividend that could become less comfortable if earnings remain depressed. A recovery depends on stronger consumer demand, successful brand improvements and restored profitability. At this valuation, the opportunity is significant, but so is the uncertainty. This review is for informational and educational purposes only, not financial advice.

Delta Plus Group has fallen dramatically, with shares recently trading around €29, close to the 52-week low of €28.80 and roughly half the 52-week high of €59.00. At this level, the market appears to be pricing in a prolonged period of weaker growth. The latest results explain the pressure. First-half 2026 revenue increased 4.6% to €196.4 million, but organic revenue declined 4.3%. Operating profit fell 2.3% to €19.6 million, while net income attributable to shareholders declined 12.7% to €9.3 million. There is also a positive side. Gross margin improved significantly from 55.7% to 57.7%, helped by product mix, pricing and purchasing costs. Recent acquisitions are contributing strongly and management is targeting further synergies and an improvement in organic performance during the second half. The balance sheet deserves attention: adjusted net debt reached €166.3 million, equivalent to 3.2 times leverage. The dividend was reduced from €1.25 in 2024 to €1.05 in 2025 and €0.75 in 2026, showing that shareholder distributions are not immune to weaker profitability. The recovery case depends on European demand improving, acquisitions delivering synergies and margins remaining strong. The main risks are weak organic growth, geopolitical disruption, debt and further earnings pressure. This review is for informational and educational purposes only, not financial advice.

Safestore Holdings is trading near a 52-week low, with shares recently around 535p, roughly 27% below their 52-week high. Yet the latest numbers raise an intriguing question: has the market become too pessimistic about a business whose underlying earnings are still growing? The first half of 2026 showed revenue rising 6.9% to £120.6 million, while adjusted earnings per share increased 2.1% to 19.4p. Underlying EBITDAR reached £67.9 million, up 3.7%. The interim dividend also increased 1% to 10.20p. However, the picture has recently softened. Third-quarter like-for-like revenue increased only 1.9%, while closing occupancy fell to 79.6% from 80.4%. Management now expects full-year adjusted earnings per share in the lower half of analyst expectations and is reviewing the timing of future developments because of economic and interest-rate conditions. The value argument is substantial property assets and an expansion pipeline expected to add £30–35 million of EBITDA after stabilization. The risks are weaker occupancy, higher financing costs, debt and falling property values. A recovery could come if occupancy improves, interest rates ease and new stores mature. The counterargument is that the current discount may reflect a prolonged period of weaker property-market returns. This review is for informational and educational purposes only, not financial advice.

Saratoga Investment has become unusually interesting for value investors: the shares recently traded around $17.57, while the latest reported net asset value was $25.59 per share. That represents a discount of roughly 31%, but the market clearly sees risks behind this valuation gap. The company generated a 9.1% return on equity for fiscal 2026, while assets under management increased 13.4%. Non-accrual investments remained low at just 0.2% of fair value. These figures suggest that portfolio performance has remained relatively resilient. Income investors may find the dividend particularly interesting. Saratoga currently declares $0.25 per share every month, equivalent to $0.75 quarterly. The annualized rate is about $3.00 per share, compared with $2.86 in fiscal 2024 and $3.31 in fiscal 2025 including a special dividend. Why is the stock down? Shares have fallen from about $18.50 at the end of August to around $17.57, while a recent leadership change may have added uncertainty. The chief financial officer is leaving in October for health-related reasons. The potential value case is the large discount to net asset value and high income. The risks include credit losses, leverage, interest-rate changes and further deterioration in portfolio valuations. The next major test comes with fiscal second-quarter results on October 6. This review is for informational and educational purposes only, not financial advice.

Scotts Miracle-Gro has just hit a fresh 52-week low, with shares recently trading around $52.29 after falling from above $56 in mid-September. For value investors, this sharp decline raises an interesting question: is the market pricing in too much bad news? The latest numbers offer both reasons for caution and reasons for interest. Third-quarter revenue increased 1% to $1.17 billion, while adjusted earnings per share rose 8% to $2.82. Management also raised its full-year adjusted earnings guidance to $4.30–$4.45 and expects $275 million of free cash flow. Net leverage improved to 3.78 times. The problem is that gross margin slipped to 31.2%, while higher freight and commodity costs remain a pressure. Heavy debt is another important risk. The recent share-price weakness appears to reflect concerns about margins, debt and the sustainability of the recovery. The dividend is attractive at $0.66 quarterly, or $2.64 annually. Importantly, the payment has remained stable through 2024, 2025 and 2026 rather than being repeatedly reduced. The potential value case is improving earnings, free cash flow, debt reduction and shareholder returns. The counterargument is leverage and uncertain margin recovery. A sustained recovery would likely require continued earnings growth and stronger cash generation. This review is for informational and educational purposes only, not financial advice.

Universal Corporation has slipped to about $43.30, near its 52-week low of $43.07. The decline reflects a deterioration in recent earnings rather than a collapse in revenue. Fiscal 2026 revenue fell 1% to $2.92 billion, but adjusted earnings per share dropped 43% to $2.64. Gross margin declined to 17.5%, while inventory write-downs and a $41.1 million goodwill impairment pushed reported earnings per share down to $1.30. The pressure continued in fiscal 2027. First-quarter revenue fell 12%, operating income plunged 93%, and Universal reported a $0.20 loss per share. Oversupply in several tobacco categories is hurting volumes, pricing and margins. Yet the valuation has a compelling feature: the company raised its quarterly dividend to $0.83, marking 56 consecutive years of dividend growth. The annualized dividend is $3.32, implying a yield above 7.5% around the current price. The value case depends on normalization of tobacco inventories, margin recovery and stronger execution in Ingredients. The main risks are prolonged oversupply, weak demand, further write-downs and dividend coverage becoming stretched. A recovery is possible if profitability rebounds, but near-term earnings visibility remains limited. This review is for informational and educational purposes only, not financial advice.

Crown Castle stock is trading near $73, about 27% below its 52-week high of $100.50. That looks painful, but the question is whether the market is pricing in too much bad news. The decline reflects weak revenue, the loss of DISH business, Sprint cancellations and cautious tower leasing expectations. In the second quarter of 2026, site rental revenue fell 4% to $967 million, while adjusted EBITDA declined 4%. However, adjusted funds from operations increased 10% to $488 million, helped by lower interest costs after the Fiber and Small Cell businesses were sold. Crown Castle received $8.4 billion of net proceeds, repaid more than $7 billion of debt and completed $1 billion of share repurchases. Management expects 2026 revenue of about $3.86 billion and adjusted funds from operations per share of $4.59. The dividend remains attractive, although it was reduced. Annual distributions were $6.26 per share in 2023 and 2024, falling to $4.75 in 2025 and about $4.25 in 2026. At the current price, that represents a yield near 5.8%. For value investors, the appeal is improving cash generation, lower debt and potential tower growth. Risks include slow leasing, cancellations, interest rates and the dividend reduction. Recovery could develop if organic growth accelerates in 2027, but patience may be required. This review is for informational and educational purposes only, not financial advice.

Nike stock has fallen to around $36, close to its lowest level in more than a decade. After such a dramatic decline, the key question is whether the market is seeing a broken business or a potential turnaround opportunity. The pressure is clear. Fiscal 2026 revenue was $46.4 billion, essentially flat, while Nike Direct revenue fell 6%. Greater China remained particularly weak, and Converse declined sharply. The company is also facing intense competition and must rebuild its product pipeline and relationships with wholesale retailers. There are encouraging signs. Fiscal 2026 gross margin improved to 42.9%, while wholesale revenue increased 6%. Management under Elliott Hill is focusing on restoring product innovation, marketplace strength and operational efficiency. The next major test comes with first-quarter fiscal 2027 results on October 1. Dividends remain attractive. The quarterly payout increased from $0.34 in 2023 to $0.37 in 2024, $0.40 in 2025 and $0.41 in 2026. At current prices, the annualized dividend is about $1.64 per share. For value investors, the attraction is the depressed valuation and recovery potential. The risks are continued weakness, shrinking profits and a turnaround taking longer than expected. A recovery is possible, but it depends on renewed revenue growth and margins. This review is for informational and educational purposes only, not financial advice.